{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:24:36Z","timestamp":1740140676280,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary gastrointestinal follicular lymphoma (PGIFL) is characterized by localized involvement of the gastrointestinal (GI) tract. PGIFL usually runs an indolent course. External beam radiation therapy is curative in a substantial proportion of localized follicular lymphomas, but GI toxicities may discourage its use in PGIFL. Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti-CD20 monoclonal antibody linked to chelator tiuxetan and radioisotope. RIT delivers confined high-intensity radiation with short path length specifically targeting lymphoma cells and sparing normal tissue. In this case series report, we included six cases of PGIFL treated with RIT. All patients had low-risk, localized, and nonbulky disease. All patients responded completely and were relapse-free for the duration of follow-up. Hematologic toxicities were seen, but none were serious. RIT is a potentially curative treatment option in PGIFL with a tolerable toxicity profile.<\/jats:p>","DOI":"10.1002\/onco.13895","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T07:20:26Z","timestamp":1625556026000},"page":"e2079-e2081","source":"Crossref","is-referenced-by-count":3,"title":["Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-2625","authenticated-orcid":false,"given":"Sanjal","family":"Desai","sequence":"first","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamad Alhaj","family":"Moustafa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Wiseman","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Witzig","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"2022011714503292800_onco13895-bib-0001","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am J Hematol"},{"key":"2022011714503292800_onco13895-bib-0002","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022011714503292800_onco13895-bib-0003","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ajh.25493","article-title":"Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma","volume":"94","author":"St-Pierre","year":"2019","journal-title":"Am J Hematol"},{"key":"2022011714503292800_onco13895-bib-0004","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1200\/JCO.2010.32.9193","article-title":"Primary follicular lymphoma of the duodenum is a distinct mucosal\/submucosal variant of follicular lymphoma: A retrospective study of 63 cases","volume":"29","author":"Schmatz","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022011714503292800_onco13895-bib-0005","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1349-7006.2011.01980.x","article-title":"Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: A multicenter, retrospective analysis in Japan","volume":"102","author":"Takata","year":"2011","journal-title":"Cancer Sci"},{"key":"2022011714503292800_onco13895-bib-0006","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00000478-200202000-00008","article-title":"Primary follicular lymphoma of the gastrointestinal tract: A clinical and pathologic study of 26 cases","volume":"26","author":"Shia","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"2022011714503292800_onco13895-bib-0007","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/PAS.0b013e318224e661","article-title":"Primary follicular lymphoma of the gastrointestinal tract","volume":"35","author":"Misdraji","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"2022011714503292800_onco13895-bib-0008","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022011714503292800_onco13895-bib-0009","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"issue":"32","key":"2022011714503292800_onco13895-bib-0010","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13895","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2079\/42203905\/oncolo_26_11_e2079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2079\/42203905\/oncolo_26_11_e2079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T17:56:13Z","timestamp":1699206973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/11\/e2079\/6508760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":10,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,21]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13895","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,7,21]]}}}